JP2005501108A - 神経変性治療におけるネフィラセタムの使用 - Google Patents
神経変性治療におけるネフィラセタムの使用 Download PDFInfo
- Publication number
- JP2005501108A JP2005501108A JP2003522525A JP2003522525A JP2005501108A JP 2005501108 A JP2005501108 A JP 2005501108A JP 2003522525 A JP2003522525 A JP 2003522525A JP 2003522525 A JP2003522525 A JP 2003522525A JP 2005501108 A JP2005501108 A JP 2005501108A
- Authority
- JP
- Japan
- Prior art keywords
- stroke
- nefiracetam
- patient
- treatment
- neurodegeneration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- NGHTXZCKLWZPGK-UHFFFAOYSA-N nefiracetam Chemical compound CC1=CC=CC(C)=C1NC(=O)CN1C(=O)CCC1 NGHTXZCKLWZPGK-UHFFFAOYSA-N 0.000 title claims abstract description 85
- 229950004663 nefiracetam Drugs 0.000 title claims abstract description 80
- 238000011282 treatment Methods 0.000 title claims abstract description 23
- 230000004770 neurodegeneration Effects 0.000 title claims abstract description 19
- 230000000694 effects Effects 0.000 claims abstract description 32
- 150000003839 salts Chemical class 0.000 claims abstract description 31
- 238000011084 recovery Methods 0.000 claims abstract description 28
- 239000003814 drug Substances 0.000 claims abstract description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 15
- 239000004480 active ingredient Substances 0.000 claims abstract description 13
- 238000004519 manufacturing process Methods 0.000 claims abstract description 13
- 208000006011 Stroke Diseases 0.000 claims description 77
- 238000000034 method Methods 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 13
- 230000006872 improvement Effects 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 239000003937 drug carrier Substances 0.000 claims description 8
- 241000124008 Mammalia Species 0.000 claims description 7
- 239000002552 dosage form Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 10
- 241001465754 Metazoa Species 0.000 description 10
- 241000700159 Rattus Species 0.000 description 8
- 230000002490 cerebral effect Effects 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 210000004556 brain Anatomy 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000000902 placebo Substances 0.000 description 7
- 229940068196 placebo Drugs 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 6
- 208000005189 Embolism Diseases 0.000 description 5
- 208000026106 cerebrovascular disease Diseases 0.000 description 5
- 230000003073 embolic effect Effects 0.000 description 5
- 230000010102 embolization Effects 0.000 description 5
- 230000031836 visual learning Effects 0.000 description 5
- GMZVRMREEHBGGF-UHFFFAOYSA-N Piracetam Chemical compound NC(=O)CN1CCCC1=O GMZVRMREEHBGGF-UHFFFAOYSA-N 0.000 description 4
- 206010037180 Psychiatric symptoms Diseases 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 239000007884 disintegrant Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000002503 metabolic effect Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- UUDAMDVQRQNNHZ-UHFFFAOYSA-N (S)-AMPA Chemical compound CC=1ONC(=O)C=1CC(N)C(O)=O UUDAMDVQRQNNHZ-UHFFFAOYSA-N 0.000 description 3
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 3
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 3
- 239000000935 antidepressant agent Substances 0.000 description 3
- 229940005513 antidepressants Drugs 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 206010008118 cerebral infarction Diseases 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 3
- 230000015654 memory Effects 0.000 description 3
- 230000003340 mental effect Effects 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 208000020016 psychiatric disease Diseases 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 208000027534 Emotional disease Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 229940051881 anilide analgesics and antipyretics Drugs 0.000 description 2
- 150000003931 anilides Chemical class 0.000 description 2
- ZXNRTKGTQJPIJK-UHFFFAOYSA-N aniracetam Chemical compound C1=CC(OC)=CC=C1C(=O)N1C(=O)CCC1 ZXNRTKGTQJPIJK-UHFFFAOYSA-N 0.000 description 2
- 230000002555 anti-neurodegenerative effect Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 230000001149 cognitive effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 230000013016 learning Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 230000001777 nootropic effect Effects 0.000 description 2
- 239000008203 oral pharmaceutical composition Substances 0.000 description 2
- IHLAQQPQKRMGSS-UHFFFAOYSA-N oxiracetam Chemical compound NC(=O)CN1CC(O)CC1=O IHLAQQPQKRMGSS-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000006886 spatial memory Effects 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- 102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 description 1
- 101710138638 5-hydroxytryptamine receptor 1A Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010008088 Cerebral artery embolism Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- -1 Cyclic GABA derivatives Chemical class 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000018899 Glutamate Receptors Human genes 0.000 description 1
- 108010027915 Glutamate Receptors Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000015336 Nerve Growth Factor Human genes 0.000 description 1
- 206010050661 Platelet aggregation inhibition Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229960000793 aniracetam Drugs 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000028600 axonogenesis Effects 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 210000001168 carotid artery common Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 208000013677 cerebrovascular dementia Diseases 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 210000003618 cortical neuron Anatomy 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000004503 fine granule Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000004295 hippocampal neuron Anatomy 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000003933 intellectual function Effects 0.000 description 1
- 201000010849 intracranial embolism Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 210000005171 mammalian brain Anatomy 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 239000003695 memory enhancer Substances 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 229940053128 nerve growth factor Drugs 0.000 description 1
- 230000007971 neurological deficit Effects 0.000 description 1
- 239000002664 nootropic agent Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229960001227 oxiracetam Drugs 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 229960004526 piracetam Drugs 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical class O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 238000012876 topography Methods 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/JP2001/007180 WO2003018005A1 (en) | 2001-08-22 | 2001-08-22 | use of nefiracetam for treating neurodegeneration |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005501108A true JP2005501108A (ja) | 2005-01-13 |
| JP2005501108A5 JP2005501108A5 (enExample) | 2008-10-16 |
Family
ID=11737657
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003522525A Pending JP2005501108A (ja) | 2001-08-22 | 2001-08-22 | 神経変性治療におけるネフィラセタムの使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20040192759A1 (enExample) |
| EP (1) | EP1420782B1 (enExample) |
| JP (1) | JP2005501108A (enExample) |
| AT (1) | ATE404192T1 (enExample) |
| CA (1) | CA2457982C (enExample) |
| DE (1) | DE60135390D1 (enExample) |
| ES (1) | ES2311537T3 (enExample) |
| WO (1) | WO2003018005A1 (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008538583A (ja) * | 2005-04-20 | 2008-10-30 | ハミルトン ファーマシューティカルズ インコーポレイティド | アパシー症候群を治療するための方法 |
| JP2009531423A (ja) * | 2006-03-28 | 2009-09-03 | ヴァレンティナ イワノフナ アカプキナ | 神経親和性、神経調節性、脳血管作用性および抗発作活性を呈する薬剤 |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107243007A (zh) * | 2008-10-16 | 2017-10-13 | 约翰斯.霍普金斯大学 | 改善认知功能的方法和组合物 |
| NO2490685T3 (enExample) * | 2009-10-22 | 2018-05-12 | ||
| CN102905532A (zh) * | 2010-02-09 | 2013-01-30 | 约翰斯.霍普金斯大学 | 用于改善认知功能的方法和组合物 |
| EP3610890A1 (en) | 2012-11-14 | 2020-02-19 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
| CN105142623A (zh) | 2013-03-15 | 2015-12-09 | 艾吉因生物股份有限公司 | 用于改善认知功能的方法和组合物 |
| EP2968237A4 (en) | 2013-03-15 | 2016-08-31 | Univ Johns Hopkins | METHOD AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION |
| US10159648B2 (en) | 2015-05-22 | 2018-12-25 | Agenebio, Inc. | Extended release pharmaceutical compositions of levetiracetam |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05163145A (ja) * | 1991-05-02 | 1993-06-29 | Dai Ichi Seiyaku Co Ltd | 脳血管性痴呆改善剤 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4749700A (en) * | 1984-10-23 | 1988-06-07 | Nastech Pharmaceutical Co, Inc. | Novel methods of administering antihistamines, antinausea and antiemetic pharmaceutical agents and novel dosage forms containing same |
| CZ281170B6 (cs) * | 1991-05-02 | 1996-07-17 | Daiichi Pharmaceutical Co., Ltd | Léčivo pro léčení demence |
| KR20010021897A (ko) * | 1997-07-15 | 2001-03-15 | 스즈키 다다시 | 건망증의 예방 또는 치료약 |
| JPH1180027A (ja) * | 1997-09-12 | 1999-03-23 | Dai Ichi Seiyaku Co Ltd | 向知性薬 |
| US6423739B1 (en) * | 2000-02-23 | 2002-07-23 | Daiichi Pharmaceutical Co., Ltd. | Method for aiding cerebral recovery following neurodegeneration |
-
2001
- 2001-08-22 US US10/487,320 patent/US20040192759A1/en not_active Abandoned
- 2001-08-22 CA CA002457982A patent/CA2457982C/en not_active Expired - Fee Related
- 2001-08-22 WO PCT/JP2001/007180 patent/WO2003018005A1/en not_active Ceased
- 2001-08-22 AT AT01958395T patent/ATE404192T1/de not_active IP Right Cessation
- 2001-08-22 DE DE60135390T patent/DE60135390D1/de not_active Expired - Lifetime
- 2001-08-22 JP JP2003522525A patent/JP2005501108A/ja active Pending
- 2001-08-22 EP EP01958395A patent/EP1420782B1/en not_active Expired - Lifetime
- 2001-08-22 ES ES01958395T patent/ES2311537T3/es not_active Expired - Lifetime
-
2007
- 2007-09-28 US US11/863,808 patent/US20080076820A1/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05163145A (ja) * | 1991-05-02 | 1993-06-29 | Dai Ichi Seiyaku Co Ltd | 脳血管性痴呆改善剤 |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008538583A (ja) * | 2005-04-20 | 2008-10-30 | ハミルトン ファーマシューティカルズ インコーポレイティド | アパシー症候群を治療するための方法 |
| JP2009531423A (ja) * | 2006-03-28 | 2009-09-03 | ヴァレンティナ イワノフナ アカプキナ | 神経親和性、神経調節性、脳血管作用性および抗発作活性を呈する薬剤 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20080076820A1 (en) | 2008-03-27 |
| EP1420782A1 (en) | 2004-05-26 |
| CA2457982A1 (en) | 2003-03-06 |
| ATE404192T1 (de) | 2008-08-15 |
| US20040192759A1 (en) | 2004-09-30 |
| ES2311537T3 (es) | 2009-02-16 |
| WO2003018005A1 (en) | 2003-03-06 |
| DE60135390D1 (de) | 2008-09-25 |
| EP1420782B1 (en) | 2008-08-13 |
| CA2457982C (en) | 2009-11-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9585878B2 (en) | Treatment of BDNF-related disorders using laquinimod | |
| US20080076820A1 (en) | Method for treating neurodegeneration | |
| JP2010507672A (ja) | アルツハイマー病を治療するための方法および組み合わせ治療 | |
| JP6466540B2 (ja) | 多発性硬化症を治療するためのＰＰＡＲγアゴニスト | |
| JPS63277623A (ja) | 医薬 | |
| JPH085787B2 (ja) | 痴呆及び脳血管障害予防・治療剤並びに血小板凝集抑制剤 | |
| CN1202826A (zh) | 1－(2－萘－2－基乙基)－4－(3－三氟甲基苯基)－1,2,3,6－四氢吡啶用于制备治疗肌萎缩性脊髓侧索硬化的药物的用途 | |
| CN115515590A (zh) | 马赛替尼用于治疗多发性硬化患者亚群 | |
| CA2368352C (en) | Method for treating neurodegeneration | |
| CN108348524A (zh) | 用于从中风恢复的方法和组合物 | |
| WO2010087313A1 (ja) | 神経突起伸展促進剤 | |
| IL269875B1 (en) | NK1 antagonist combination and a method for the treatment of synucleinopathies | |
| JP2010524905A (ja) | 脊髄損傷を治療するための４−シクロプロピルメトキシ−ｎ−（３，５−ジクロロ−１−オキシドピリジン−４−イル）−５−（メトキシ）ピリジン−２−カルボキサミドの使用 | |
| RU2258506C2 (ru) | Лекарственные средства для предупреждения и лечения нейродегенеративных заболеваний | |
| JP3494651B2 (ja) | 神経変性疾患の治療を目的とする医薬生成物の製造のためのエファロキサンおよびその誘導体の使用 | |
| JP4598674B2 (ja) | 統合失調症治療剤 | |
| JPWO2001013911A1 (ja) | 高血圧性細動脈障害抑制剤 | |
| JP2008184396A (ja) | 神経損傷に起因する身体機能障害の予防及び治療のための医薬 | |
| WO2005097138A2 (en) | Combinations comprising oxcarbazepine to treat affective disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20060221 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20060425 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060629 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080819 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080819 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110826 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20111019 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20111026 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20120507 |